Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Azalea Health Adds to its EMR Offerings
Digital health deals are on track to surpass 2016’s record 157 transactions. Through mid-October, 139 deals have been announced in this sector, targeting companies specializing in revenue cycle management, telemedicine and electronic medical records (EMRs). Just four companies have made more than one acquisition this year, indicating there are more buyers getting into digital health than leaving it. Among the four serial acquirers this year are Allscripts (NASDAQ: MDRX), Azalea Health, NextGen Healthcare Information (NASDAQ: QSII) and contract research organization PRA Health Sciences (NASDAQ: PRAH). Azalea Health is the only the privately held digital health company to announce... Read More »
Stat of the Week: Q3:17 Deal Volume Down 10%
As third quarters go in the cycle of healthcare mergers and acquisitions, big news is not expected. First quarter results may be exciting if the previous year’s fourth quarter was so hectic that a number of deals were pushed into the next year. Second quarters are usually a pause for breath as more books begin to circulate, indicating sellers’ interest in closing a deal by the end of the year. Third quarters tend to stay quiet, or even go dormant. Holidays and vacations are blamed, but for many deal makers, it’s a time to study and gird for the fourth quarter, when regulatory and tax deadlines sometimes loom. Preliminary results for Q3:17 show it is following the typical pattern. With 334... Read More »CryoLife Misses Q3 Revenues, Buys JOTEC
Third quarter earnings season is off to a bad start for Cryolife, Inc. (NYSE:CRY), maker of medical devices and tissue processing systems focused on cardiac and vascular surgery. CRY stock slumped on Wednesday, October 11, when the company reported Q3 revenues of $45.1 million, well below its previously announced guidance of $46.5 million to $47.5 million. Not even an acquisition turned the stock northward, and it stayed down about 16% throughout the day. On October 10, Cryolife announced the acquisition of German medical device developer JOTEC AG, which makes technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on... Read More »
Deal of the Week: Express Scripts Diversifies
Express Scripts (NASDAQ: ESRX) didn’t hedge its bets that online retail giant Amazon will enter the prescription drug delivery market. On October 10, the leading pharmacy benefit manager (PBM) acquired South Carolina-based eviCore healthcare from its current investors, including General Atlantic, TA Associates, and Ridgemont Equity Partners, for $3.6 billion. The deal follows rumors that Amazon is contemplating entering the prescription drug delivery market in an attempt to improve price transparency for consumers and reduce out-of-pocket costs. Last April, Express Scripts lost Anthem, Inc. (NYSE: ANTM) as a client, and with it, 18% of annual revenue. The threat of... Read More »
Third Quarter Long-Term Care M&A Results Are In
We will be addressing the quarterly seniors housing and healthcare M&A results in Health Care M&A Quarterly Report, which covers all 13 health care sectors. But, here is a preview: Although it remained above 70 deals for the quarter, seniors housing and care M&A activity fell to a year-low, tying with last year’s third quarter at 71 publicly announced transactions. Dollar volume also fell from its recent peak of $9.7 billion in the second quarter of 2017, recording $2.5 billion in transaction value based on disclosed prices. Increasingly, we have seen buyers prefer the one-off deals that come with one or two properties. Those deals are easier to complete and are most... Read More »Health Care M+A Weekly Deals, The Week Ending October 6, 2017
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Behavioral Health Care Acquirer Target Price D’Amore Healthcare, Inc. Pat Moore Foundation N/A Biotechnology Acquirer Target Price Gesynta Pharma AB Rights to OX-MPI program N/A BlueRock... Read More »
Stat of the Week: September 2017 Deal Volume
It was business as usual for healthcare deal makers in September 2017. The 118 transactions we’ve captured to this point are 9% ahead of August’s deal volume (108 deals), but down 13% compared with the same month in 2016 (135 deals). If you’ve read this column at all in 2017, you’re not surprised. The market is still transitioning toward value-based care and reimbursement, and that’s boosted a couple of sectors, and given others pause. One sector that’s seen deal volume wax over the past 18 months is Physician Medical Groups. Only six transactions surfaced in September 2017 (-33% vs. August, and -50% from a year ago), but the deals aren’t over yet. Private physician practices still face... Read More »
Deal of the Week: Boston Scientific/Apama
Boston Scientific Corporation (NYSE: BSX) announced its second acquisition of the year, targeting privately held Apama Medical Inc. in a deal for $175 million. That’s small potatoes compared with its previously announced deal for Symetis SA, the Swiss maker of transcatheter aortic valve implantation devices, for $435 million. The Apama transaction consists of $175 million in cash up-front and a maximum of $125 million in contingent payments over the period of 2018-2020 based on achievements of clinical and regulatory milestones. Based in California, Apama Medical is developing radiofrequency balloon catheter system for the treatment of atrial fibrillation (AF). AF, a heart rhythm... Read More »
Amgen Teams with CytomX
Oncology is driving some big deals, no question about it. More than 350 deals have had targets involved in some form of oncology program or drug since 2012. In the first week of October alone, we saw three deals targeting some form of oncology treatment. The one with the largest potential pay-off was announced between Amgen Inc. (NASDAQ: AMGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX). The deal has potential value of more than $1.5 billion. In this strategic collaboration, the companies will co-develop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types. Probody... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
